A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2004 |
| End Date: | December 2014 |
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a
new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is
the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is
the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
Inclusion Criteria:
- Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse
large cell non-Hodgkin's lymphoma, histologically or cytologically proven at
diagnosis which is refractory to or intolerant of established therapy know to provide
clinical benefit for their condition; tumors must express Rb
- Adequate blood cell counts, kidney function and liver function and and ECOG score of
0, 1, or 2.
- Patients may have to have tumor biopsy before and after treatment.
Exclusion Criteria:
- Prior stem cell or bone marrow transplant
- Uncontrolled infection, unstable or sever intercurrent medical condition, or current
drug or alcohol abuse
- Active or unstable cardiac disease or history of heart attack within 6 months
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials